LLY Ticker Curator

• Pill milestone: FDA approved 25mg oral semaglutide Wegovy in late 2025 for chronic weight management, first such GLP-1 pill.
• CV coverage hack:...

Eli Lilly's retatrutide stands out as a next-gen obesity drug with longevity potential.

• Triple mechanism: Activates GIP, GLP-1, and glucagon...

• Daily lag: +2.39% trails S&P 500's 2.51%, Dow's 2.85%, Nasdaq's 2.8%
• Recent underperformance: -7.02% vs Medical sector -5.12%, S&P -1.66%
  -...

Aggressive expansion via Foundayo pill launch and $6.3B Centessa buyout fuels post-earnings momentum.

• Foundayo rollout: Oral GLP-1 now nationwide,...

Broad institutional accumulation underscores faith in LLY's obesity dominance and pipeline:

• BIP Wealth +161% to 3,673 shares (~$3.95M)
• Capital...

• Prime Capital boosted its LLY holdings by 2.5% in Q4, acquiring 1,744 shares to reach 70,722 shares worth $76M (0.9% of portfolio, 25th position).
  -...

Major Acquisition

• 🔥 Centessa Deal: Eli Lilly to acquire Centessa Pharmaceuticals for $38 per share cash plus up to $9 contingent value right,...

Growing institutional interest in Eli Lilly persists, with 82.53% ownership:

• Jefferson Bridge opens new stake of 1,760 shares ($1.89M, 1.9% of...

Jim Cramer names Eli Lilly (LLY) a favorite set to lead weight loss drugs.

• Flexible pill: Take anytime, no food worries—beats rivals like Novo.
  -...

Deal Breakdown:

• Lilly buys all Centessa shares at $38 cash per share + CVR worth up to $9 if milestones hit (total $47).

Centessa's Neuro Focus:
-...

• 1LLY-IT last at 799.90 EUR (04/10/26 CEST), down -16.00 (-1.96%)
• Volume: just 527 shares amid 52-week range 535.20 - 972.00 EUR
• Snapshot shows mid-range price on low liquidity in Milan trading

Eli Lilly's expanding obesity empire drives analyst optimism and long-term dominance:

• Rothschild & Co Redburn hikes PT to $880 from $875, neutral...

Eli Lilly to buy Centessa Pharma for up to $7.8 billion, bolstering Alkermes' pipeline of drugs to treat sleep-wake disorders.

Analyst Ratings

• 🔥 Morgan Stanley PT Raise: Morgan Stanley raised its price target on Eli Lilly to $1,327 from $1,313 while maintaining an...

• Cane Capital starts new LLY position: 2,407 shares worth $2.587M in Q4, 1% of holdings.
• Others pile in: Brighton Jones up 22% to 9,597 shares;...

Novo Nordisk's edge in oral obesity drugs: its Wegovy pill is already in pharmacies, while LLY's oral GLP-1 awaits later 2026 U.S. approval.

Key...

Analysts highlight undervaluation as a buy signal for LLY:

• At $940, 29% below consensus target and 17% off 52-week high
• RBC reiterates rating on...

Rapid rollout of Eli Lilly's Foundayo (orforglipron) to LifeMD patients via LillyDirect boosts obesity treatment accessibility.

• FDA-approved April...

Eli Lilly aggressively invests in AI via a global R&D deal with Insilico Medicine, worth up to $2.75 billion in milestones and $115 million...

• MS PT hike: Raised to $1,327 (from $1,313), overweight rating implies 41.32% upside from ~$939.
• Earnings momentum: Q EPS $7.54 (beat $7.48), rev...